AIT Therapeutics Inc
| File:AIT Therapeutics Logo.png | |
| Private | |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | 2011 |
| Founder 👔 | |
| Headquarters 🏙️ | , , |
Area served 🗺️ | |
Key people | Steven Lisi Amir Avniel Yossef Av-Gay |
| Products 📟 | Inhaled Nitric Oxide, Medical Device |
| Members | |
Number of employees | |
| 🌐 Website | ait-pharm |
| 📇 Address | |
| 📞 telephone | |
AIT Therapeutics Inc. is a publicly held clinical stage anti-microbial therapeutic company formed in 2011 and based in Ness Ziona, Israel, that develops technology to safely deliver nitric oxide gas for the treatment of respiratory infections such as severe bronchiolitis, cystic fibrosis related lung infection (CF), non-tuberculosis mycobacterial (NTM), and drug-resistant lung infections. The technology is based on inhaled nitric oxide studies originated at the University of British Columbia, Vancouver, Canada.
Inhaled nitric oxide[edit]
Nitric oxide is a naturally produced molecule by body’s innate immune system that provides a first line of defense against a broad spectrum of bacterial and viral pathogens. Nitric oxide was largely known as a pollutant until 1987, when it was identified as the endothelium-derived relaxing factor.[1] In 1991, inhaled nitric oxide was proven to be potent pulmonary vasodilator in patients with pulmonary hypertension and two years later it emerged as a potential therapy for the acute respiratory distress syndrome (ARDS).[2] These studies later led to the approval of inhaled nitric oxide therapy by US Food and Drug Administration (FDA) for hypoxic respiratory failure of the term and near-term newborn patients.[3] The broad-spectrum antibacterial and antiviral activities of nitric oxide and the difficulty for pathogens to develop resistance against it, has led to ongoing investigations in the application of inhaled nitric oxide for treatment of chronic and/or drug-resistant lung infections.[4][5]
External links[edit]
1998 Nobel Prize in Physiology/Medicine for discovery of nitric oxide signaling
Inhaled Nitric Oxide Therapy in Adults (New England Journal of Medicine Review)
Cystic Fibrosis News Today - AIT in the news
References[edit]
- ↑ Palmer RM et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526
- ↑ Griffiths MJD and Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353:2683-95
- ↑ https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20845_INOmax_Approv.pdf
- ↑ Fang, Ferric C. (October 2004). "Antimicrobial reactive oxygen and nitrogen species: concepts and controversies". Nature Reviews. Microbiology. 2 (10): 820–832. doi:10.1038/nrmicro1004. ISSN 1740-1526. PMID 15378046.
- ↑ Levy SD et al. High-flow oxygen therapy and other inhaled therapies in intensive care unit. Lancet. 2016; 387(10030):1867-78)
This article "AIT Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
